Posts by Hanny Al-Samkari, MD
-
Trial Co-led by Mass General Leads to Oral Drug Approval for Red Blood Cell Disorder
A Phase 3 clinical trial conducted by Massachusetts General Hospital researchers and an international team of colleagues has led to the FDA's approval of an oral drug for treatment of adults with pyruvate kinase deficiency, a rare red blood cell disorder.
-
Developing Therapeutics for Benign Hematologic Diseases
Hanny Al-Samkari, MD, is a classical hematologist and clinical investigator at the Center for Hematology at the Mass General Cancer Center. Here he discusses his research on the use of systemic therapies to treat hereditary hemorrhagic telangiectasia.
-
Prothrombin Fragment 1.2 Predicts Thrombosis in Hospitalized Patients with COVID-19
Prothrombin fragment 1.2, a serologic marker of coagulation activation, identified which patients hospitalized for COVID-19 would develop thrombosis, and it was more discriminant than D-dimer.
-
Early Data Suggest Caution with Empiric Escalation of Anticoagulation in COVID-19
A substantial rate of bleeding in patients with COVID-19 suggests caution with routine escalation of anticoagulation beyond standard doses.
-
Is There a Connection Between Blood Type and COVID-19? Q&A with Rebecca Karp Leaf, MD, and Hanny Al-Samkari, MD
In this Q&A, Rebecca Karp Leaf, MD, and Hanny Al-Samkari, MD, of Massachusetts General Hospital, give us a rundown of what is known to date about the correlation between blood type and COVID-19 transmission/severity, findings from their study and why this connection may or may not exist.
-
Medical Grand Rounds: Unraveling the Mystery of Clotting in COVID-19
On May 7, 2020, the ninth lecture in the Medical Grand Rounds' COVID-19 series featured a panel of experts who are investigating blood clotting in COVID-19 patients.
Biography
Dr. Hanny Al-Samkari is a hematologist and clinical investigator at the Massachusetts General Hospital and Harvard Medical School. He received his medical degree from Washington University in St. Louis, completed his residency in internal medicine at the Hospital of the University of Pennsylvania (where he also served as Chief Medical Resident), and completed his fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute-Massachusetts General Hospital combined program. He specializes in disorders of bleeding and clotting as well as hemolytic anemias. This includes hereditary hemorrhagic telangiectasia, immune thrombocytopenia, chemotherapy-induced thrombocytopenia, pyruvate kinase deficiency, thalassemia, hemophilia, von Willebrand disease, and other blood diseases. As a clinical investigator, Dr. Al-Samkari serves as the principal investigator for several clinical trials at any given time for these diseases and is able to offer new treatment options to these patients.
Dr. Al-Samkari also serves as the Associate Director of the multidisciplinary Massachusetts General Hospital Hereditary Hemorrhagic Telangiectasia Center of Excellence. Patients with hereditary hemorrhagic telangiectasia seeking care at our internationally-recognized center are encouraged to schedule an appointment with Dr. Al-Samkari.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
